Introduction {#S1}
============

Intraocular metastases from malignant melanomas usually affect sites favored by primary intraocular melanoma---namely, the uveal tract---but can also affect the optic disc, retina, and vitreous ([@B1]--[@B5]). Orbital metastases from any malignancy are rare, and metastatic melanoma accounts for 5--20% of these, with primary sites usually being the skin, uvea, or ocular surface ([@B6]--[@B11]). Late presentation of secondary orbital melanoma has occasionally been reported, with the longest disease-free interval being 40 years after enucleation for a choroidal melanoma ([@B12]), but in general, these patients have been reported to have very poor survival---the average being 5.7--19.7 months ([@B10], [@B13], [@B14]).

In this work, we extend the knowledge of the clinical presentation and therapeutic strategies for patients with secondary melanoma within the orbit, including patients with anatomically contiguous disease (e.g., local progression or local recurrence of ipsilateral ocular disease/sinus disease) and those with true metastatic disease (e.g., contralateral ocular disease or distant cutaneous sites). In particular, focus is placed on two unusual groups: first, those patients with a long interval between primary disease and orbital disease and, second, those with a long survival after treatment of melanoma within the orbit.

Patients and Methods {#S2}
====================

Patients seen within the Orbital Unit at Moorfields Eye Hospital, between 1982 and 2016, with biopsy-proven orbital melanoma were identified from a diagnostic database, and the clinical case-notes and imaging were reviewed (where available). Patients with proven primary orbital melanoma (e.g., *without* evidence of ipsilateral intraocular, ocular surface, or sinus disease) were excluded. For this study, "late" orbital recurrence was regarded as being 3 or more years after treatment of the primary tumor, and "long survival" was 4 or more years after diagnosis of secondary orbital disease. The study was conducted in accordance with the Declaration of Helsinki. All participants had given written, informed consent for inclusion of data in studies prior to surgery or treatment. Local ethics board (Moorfields Eye Hospital NHS Foundation Trust) approved the study under the retrospective analysis of data procedures (ROAD17/010).

Survival analysis was estimated using standard Kaplan--Meier survival plots (on MedCalc); normality of data was assessed using Shapiro--Wilks testing, and comparison of means was performed using Mann--Whitney *U*-testing for non-parametric data.

Results {#S3}
=======

Eighty-nine patients were identified with secondary orbital melanoma during the study period, with complete clinical data available for 48 (54%) patients (Table [1](#T1){ref-type="table"}), and partial data---including mortality data---for a further 21 patients (24%) (Table [2](#T2){ref-type="table"}); only very limited data were available for 20 patients. The commonest primary source of tumor was choroidal melanoma (45/89; 51%); conjunctival melanoma was the next most frequent (15/89; 17%), and cutaneous, eyelid, and naso-sinus tumors occurred in a few cases; the primary origin could not be ascertained in 11/89 (12%) cases due to disseminated disease at presentation (Figure [1](#F1){ref-type="fig"}). The mean age at presentation with secondary orbital disease was 65 years (median 63; range 31--97 years). There was no significant gender bias, with 50 affected women and 39 men (χ^2^ = 2.72, *p* \> 0.05); this lack of gender bias persisted after being stratified by the decade of presentation (*p* \> 0.05). Most patients were white northern Europeans, but four were of Mediterranean origin, one from the Middle East, and one from North Africa.

###### 

Clinical characteristics of 48 patients with orbital malignant melanoma secondary to a primary tumor elsewhere, classified by the site of primary tumor and the survival interval after presentation with orbital disease.

  Sex   Site of primary tumor   Age at presentation with primary tumor   Therapy for primary tumor   Age at secondary orbital disease (years)   Interval between primary therapy and orbital presentation (months)   Side   Treatment for secondary orbital disease   Orbital progression   Systemic progression   Interval between primary therapy and latest follow-up (months)   Survival after orbital treatment (months)   Age at death (years)
  ----- ----------------------- ---------------------------------------- --------------------------- ------------------------------------------ -------------------------------------------------------------------- ------ ----------------------------------------- --------------------- ---------------------- ---------------------------------------------------------------- ------------------------------------------- ----------------------
  M     Choroid                 77                                       Enucleation                 79                                         32                                                                   L      Palliation                                                                             34                                                               2                                           79
  F     Choroid                 89                                       Incisional biopsy           89                                         0                                                                    L      Incisional biopsy                         N                     Y                      3                                                                3                                           89
  F     Choroid                 73                                       Incisional biopsy           73                                         0                                                                    L      Incisional biopsy + RT                    N                     N                      14                                                               14                                          75
  M     Choroid                 49                                       Local resection             72                                         282                                                                  L      Debulking + chemotherapy                  Y                     Y                      299                                                              17                                          73
  M     Choroid                 47                                       Enucleation                 57                                         114                                                                  R      Radiotherapy                                                                           138                                                              24                                          58
  F     Choroid                 69                                       Enucleation                 69                                         6                                                                    R      Exenteration                              N                     Y                      30                                                               24                                          71
  F     Choroid                 68                                       Exenteration + RT           68                                         0                                                                    R      (Exenteration + RT)                       U                     U                      24                                                               24                                          70
  F     Choroid                 67                                       Enucleation + RT            67                                         1                                                                    L      Debulking                                 Y                     N                      26                                                               25                                          69
  M     Choroid                 37                                       Refused therapy             41                                         49                                                                   R      Exenteration + RT                         Y                     Y                      84                                                               35                                          43
  F     Choroid                 72                                       Palliation                  72                                         0                                                                    L      (Palliation)                              N                     Y                      39                                                               39                                          75
  F     Choroid                 53                                       Enucleation                 54                                         11                                                                   R      Exenteration + RT                         N                     Y                      53                                                               42                                          57
  F     Choroid                 59                                       Exenteration                59                                         0                                                                    R      (Exenteration)                            N                     Y                      56                                                               56                                          63
  M     Choroid                 23                                       RT                          44                                         262                                                                  L      Debulking + RT                            Y                     Y                      322                                                              60                                          49
  M     Choroid                 71                                       Enucleation                 71                                         0                                                                    R      (Enucleation)                             N                     N                      105                                                              105                                         80
  M     Choroid                 63                                       Exenteration + RT           63                                         0                                                                    R      (Exenteration + RT)                       N                     N                      134                                                              134                                         74
  M     Choroid                 60                                       Enucleation                 62                                         25                                                                   L      Exenteration                              N                     N                      184                                                              159                                         75
  M     Choroid                 5                                        Enucleation                 39                                         416                                                                  R      Exenteration                              N                     N                      814                                                              398                                         72
  F     Choroid                 62                                       Exenteration + RT           62                                         0                                                                    R      (Exenteration + RT)                       N                     N                      17                                                               17                                          N/A
  F     Choroid                 41                                       Exenteration + RT           41                                         0                                                                    L      Exenteration + RT                         N                     Y                      30                                                               30                                          N/A
  M     Choroid                 41                                       Enucleation                 60                                         239                                                                  R      Debulking + RT                            N                     N                      412                                                              173                                         N/A
  F     Choroid                 36                                       Enucleation                 53                                         208                                                                  R      Excisional biopsy + RT                    Y                     N                      398                                                              190                                         N/A
  M     Choroid                 48                                       Enucleation                 49                                         16                                                                   L      Exenteration                              N                     Y                                                                                       Lost to follow-up                           Died date unknown
  F     Choroid                 54                                       RT                          58                                         56                                                                   L      Exenteration + RT                         N                     N                                                                                       Lost to follow-up                           Died date unknown
  F     Conj                    70                                       Exenteration                70                                         0                                                                    R      Exenteration                              N                     Y                      2                                                                2                                           70
  F     Conj                    82                                       Excisional biopsy           82                                         8                                                                    R      Exenteration                              U                     Y                      46                                                               38                                          71
  M     Conj                    55                                       Local resection             56                                         12                                                                   R      Excisional biopsy                         Y                     Y                      208                                                              196                                         73
  F     Conj                    87                                       Local resection + RT        97                                         120                                                                  L      Exenteration                              N                     N                      124                                                              4                                           N/A
  M     Conj                    69                                       Local resection + RT        75                                         80                                                                   R      Exenteration + chemotherapy               N                     Y                      87                                                               7                                           N/A
  M     Conj                    65                                       Local resection             69                                         51                                                                   R      Excisional biopsy                         N                     N                      70                                                               29                                          N/A
  F     Conj                    48                                       Local resection             59                                         128                                                                  R      Exenteration                              N                     Y                      164                                                              36                                          N/A
  F     Conj                    65                                       Local resection + RT        65                                         11                                                                   L      Debulking                                 Y                     Y                      63                                                               52                                          N/A
  M     Conj                    87                                       Exenteration                87                                         0                                                                    R      Exenteration                              N                     Y                      59                                                               59                                          N/A
  F     Conj                    60                                       Nil                         61                                         6                                                                    L      Exenteration                              N                     N                      246                                                              240                                         N/A
  M     Skin                    36                                       Local resection             43                                         87                                                                   L      Debulking + chemotherapy                  N                     Y                      89                                                               2                                           43
  F     Skin                    44                                       Local resection             63                                         234                                                                  L      Excisional biopsy                         N                     Y                      240                                                              6                                           64
  F     Skin                    58                                       Palliation                  58                                         0                                                                    R      Palliation                                N                     Y                      8                                                                8                                           58
  M     Skin                    86                                       Local resection             88                                         28                                                                   R      Palliation                                Y                     Y                      36                                                               8                                           88
  F     Skin                    51                                       Local resection             57                                         83                                                                   L      Incisional biopsy + chemotherapy          N                     Y                      96                                                               13                                          59
  M     Skin                    31                                       Local resection             34                                         52                                                                   BOTH   Extensive resection                       U                     U                      72                                                               20                                          36
  M     Skin                    51                                       Local resection             60                                         121                                                                  R      Biopsy + chemotherapy                     N                     Y                      142                                                              21                                          62
  F     Skin                    32                                       Local resection             64                                         362                                                                  L      Exenteration                              N                     N                      363                                                              1                                           N/A
  F     Skin                    54                                       Local resection             60                                         79                                                                   L      Exenteration + RT                         N                     N                      87                                                               8                                           N/A
  M     Skin                    54                                       Local resection             71                                         205                                                                  L      Debulking                                                       Y                      295                                                              90                                          N/A
  F     Skin                    65                                       Local resection             67                                         41                                                                   R      Debulking + RT                            N                     Y                      191                                                              150                                         N/A
  M     Unknown                 61                                       Palliation                  61                                         0                                                                    R      Palliation                                N                     Y                      4                                                                4                                           61
  F     Nasal                   54                                       Local resection             67                                         161                                                                  L      Debulking                                 Y                     Y                      201                                                              45                                          71
  F     Nasal                   57                                       Local resection             61                                         48                                                                   L      Debulking + RT                            U                     Y                      101                                                              53                                          64
  F     Sinus                   59                                       Local resection             59                                         1                                                                    L      Debulking + RT                            N                     N                      100                                                              99                                          N/A

*RT, radiotherapy*.

*Gray shaded cases can be considered truly metastatic disease, whilst non-shaded cases are likely to represent local spread or local micrometastasis*.

###### 

Survival after presentation with secondary orbital melanoma in 21 patients for whom date of death is known, without other complete clinical data; classified by origin of the primary tumor.

  Sex   Age at orbital presentation (years)   Site of primary melanoma   Age at death (years)   Survival after presentation with secondary orbital disease (months)
  ----- ------------------------------------- -------------------------- ---------------------- ---------------------------------------------------------------------
  M     57                                    Choroid                    58                     8
  F     82                                    Choroid                    83                     20
  M     64                                    Choroid                    64                     20
  M     63                                    Choroid                    66                     38
  M     54                                    Choroid                    57                     42
  F     86                                    Choroid                    91                     66
  F     75                                    Choroid                    85                     125
  F     47                                    Choroid                    74                     328
  M     63                                    Conjunctiva                64                     21
  F     81                                    Conjunctiva                83                     32
  F     60                                    Conjunctiva                65                     63
  M     78                                    Conjunctiva                90                     140
  F     64                                    Nasal                      64                     1
  M     63                                    Sinus                      63                     3
  F     53                                    Unknown                    53                     3
  M     61                                    Unknown                    60                     5
  F     62                                    Unknown                    64                     25
  F     75                                    Unknown                    78                     50
  F     63                                    Unknown                    69                     70
  F     67                                    Unknown                    73                     73
  M     87                                    Unknown                    70                     89

*Patients classified as having "unknown" origin for their primary tumor had extensive systemic disease at presentation and poorly differentiated histology, this precluding a conclusive diagnosis of the primary site*.

![Sites of primary origin for malignant melanomas for 89 patients presenting with melanoma in the orbit.](fonc-07-00125-g001){#F1}

The interval between the diagnosis of primary tumor and the later detection of orbital disease (the "orbital disease-free interval") was available for 48/89 (54%) patients. This showed a wide variation, with 13/48 (27%) patients having orbital disease found at the time of primary diagnosis, but others presenting many years later; indeed, the longest orbital disease-free interval was over 34 years (Table [1](#T1){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). Twenty-three (23/48; 48%) patients were considered to have had late orbital disease---that is, at more than 36 months after primary tumor---and 17/23 (74% of the late recurring tumors) had very late recurrence (\>6 years after primary disease). The commonest primary origin for late recurrent orbital tumors was skin (9/23 cases; 39%) or uveal tract (8/23; 35%).

![Interval from the time of diagnosis of primary melanoma to the appearance of orbital disease in 48 patients presenting with melanoma in the orbit. Patients were considered to have "late recurrence" when orbital disease presented more than 3 years after the primary diagnosis elsewhere.](fonc-07-00125-g002){#F2}

Of 69 patients whose mortality data were available in May 2016, 52 had died (47/52 known tumor-related deaths) at a median of 24 months after orbital diagnosis (range 2 months to 33.2 years). Patients with tumors of cutaneous or unknown origin had worst survival, conjunctival had the best, and choroidal had the second best survival (Figure [3](#F3){ref-type="fig"}). There was no correlation between the orbital disease-free interval and overall survival (r = --0.16; one outlier value excluded) (Figure [4](#F4){ref-type="fig"}). The overall survival after orbital disease patients was similar in patients with early and late orbital recurrence (*U* = 162, *Z* = −0.399, *p* = 0.689); this latter analysis was performed excluding any patients presenting after May 2012 to avoid bias favoring the "early-recurring" group. Furthermore, the patients with locally progressive or locally recurrent secondary disease had similar survival to that of the patients with metastatic secondary disease (*U* = 97.5, *Z* = 0.400, *p* = 0.690). The median follow-up for the 17 known living patients is 44 months (range 1--190 months), suggesting a relatively good survival in this group.

![Kaplan--Meier survival analysis for 69 patients with orbital melanoma secondary to primary disease at another site, classified by origin of the primary tumor.](fonc-07-00125-g003){#F3}

![Survival time after presentation with orbital disease in 69 patients, as related to the interval between primary tumor diagnosis and orbital presentation.](fonc-07-00125-g004){#F4}

Sixteen patients survived 4 years or more after orbital diagnosis (range 52--398 months), and eight are still alive (surviving to-date 52--190 months); the primary tumor was from choroid (eight cases), conjunctiva (four cases), skin (two cases), or sinus (two cases).

Surgical Approaches in Secondary Orbital Melanoma {#S3-1}
-------------------------------------------------

Where imaging showed diffuse orbital disease, an incisional biopsy was performed without any mobilization of bone, and, where orbital disease was causing major disfigurement, the patient was later considered for palliative orbital exenteration. However, in many cases, secondary orbital melanoma formed a well-defined mass at the time of presentation, and, in such cases, the mass was excised intact through a bone-sparing anterior orbitotomy. Where macroscopically intact excision was not possible, the lesion was, as far as possible, meticulously isolated from the "normal" neighboring tissues, and then piecemeal excision of the mass (debulking) was performed.

Discussion {#S4}
==========

A retrospective analysis has been performed for 89 patients presenting with biopsy-proven secondary orbital melanoma in a tertiary-referral orbital unit; this analysis included two closely related classifications of secondary orbital of tumor---those that were locally progressive/recurrent and those that had metastasized from distant sites. There were two notable features in the patient group: first, orbital involvement tends to occur either early (\<1 year after primary disease) or late at many years after primary disease (Figure [2](#F2){ref-type="fig"}). Second, there was a group of patients with an unusually long survival after the diagnosis of melanoma recurrence within the orbit.

Thirteen patients had orbital melanoma as the presenting symptom of a primary melanoma arising elsewhere; 11 of these were---somewhat predictably---ocular primary tumors with local disease progression; one primary tumor was, however, a distant cutaneous lesion, and one patient had widespread systemic disease and thus primary origin was not discernible. Late recurrence of choroidal melanoma is, however, fairly common---with 9% of recurrences occurring at 5--10 years after treatment ([@B15]). Of our 48 patients with complete follow-up, the time from initial diagnosis to presentation with orbital disease varied from 0 months to \>34 years; remarkably, 23/48 (48%) had late secondary local recurrence, with an interval of 36 months or more between primary disease and orbital recurrence. This propensity for late orbital recurrence might, therefore, suggest that a disease-free interval of 10 years should not be considered a definite "cure" for malignant melanoma.

The reason for the long interval between primary disease and orbital recurrence in our patients is conjectural, but it might be related to immune-mediated control of tumor growth. Tumor-specific lymphocytes that target malignant cells through recognition of tumor-associated antigens---such as tyrosinase, Melan-A/MART-1, gp100, TRP-1, and TRP-2---have been isolated from melanoma ([@B16]). Furthermore, melanomas showing spontaneous regression contain more tumor-specific lymphocytes than those in non-regressing tumors, and the presence of these lymphocytes portends a better prognosis ([@B17], [@B18]). High levels of immunosurveillance within the orbit might, therefore, maintain micro-metastases of primary tumor in remission for many years; later, mutations might occur in tumor-associated antigens, leading to loss of lymphocytic recognition and, thereby, loss of tumor control. Alternatively, detrimental changes in the immune system (such as pregnancy, immunocompromise, or aging) might lead to reduced efficiency of immune surveillance, with emergence of growth in previously well-controlled micro-metastases.

Although choroidal melanoma was the commonest primary source for orbital melanoma, cutaneous melanoma is the most likely to have late orbital secondary disease. In a previous study of over 500 metastatic skin cancers, early metastasis (\<3 years after surgery) was found to be significantly associated with past history of non-melanoma skin cancer, thicker lesions (Breslow depth), and ulcerative melanomas ([@B19]). In contrast, a history of *non-ulcerative* melanoma was found to be associated with late recurrence (\>8 years after primary disease), this being consistent with our observation of tendency for orbital metastases of cutaneous melanoma to be a late phenomenon.

Published survival rates for melanoma within the orbit range from 6 to 20 months ([@B10], [@B13], [@B14]). There were 52 deaths (47 tumor-related) among our 69 patients with known outcome (75%), but only 11/52 (21%) fell within this previously published survival range, and 7/52 (13%) had less than 6 months survival. Moreover, 34/52 (65%) patients survived \>20 months, and 19/34 (55.8%) survived \>4 years. Of the 17 surviving patients in May 2016, 8 (47%) have survived more than 4 years. Our study would suggest that secondary malignant melanoma within the orbit can follow a relatively indolent course after treatment, with a survival much better than expected---thus making prognosis for this condition hard to predict.

Treatment of secondary orbital melanoma remains controversial and is often palliative ([@B20]). Surgery remains the mainstay of treatment, with local resection, debulking, or exenteration being the primary choices. Radiotherapy and chemotherapy can be considered, and their use takes into account life expectancy and the presence of other metastatic diseases (e.g., bony metastases). Local radiotherapy is the most commonly used adjuvant therapy when there are no distant metastases ([@B10]), and 16/48 of our patients had local radiotherapy. Chemotherapy was used in 4/48 (9%) of our patients and played a role when there is systemic metastatic disease at orbital presentation (e.g., bone or liver lesions). The scenario for melanoma chemotherapy is, however, changing rapidly with the advent of immunotherapy; cutaneous and uveal melanomas are biologically distinct, and, as such, they would be expected to require distinct treatments. Immunotherapy for metastatic cutaneous melanoma markedly improves survival, with the most dramatic being ipilimumab and nivolumab combination therapy ([@B21]). Several agents have been approved by FDA and NICE for monotherapy, while combination therapies undergo Phase III trials, but there is no evidence yet for the impact these may have in orbital metastases---a potential area for further research.

By contrast, ipilimumab has demonstrated only modest benefits in treating primary uveal melanoma. There are a variety of new agents that might provide benefit in metastatic uveal melanoma; these include verteporfin (previously used in wet age-related macular degeneration), arylsulfonamides, and anti-VEGF agents ([@B22]). Arylsulfonamides such as KCN1 inhibit hypoxia-inducible factors, thereby depriving cancer cells of their ability to thrive in a hypoxic environment ([@B23]). Anti-VEGF agents such as bevacizumab have been postulated as possible treatments because of the high VEGF levels seen in uveal melanoma. Clinical trials relating to these are all in early human phases but have demonstrated significant benefits in mouse models. These potential treatments of secondary orbital melanoma require further investigation, but they may herald a new era where metastatic melanoma is no longer a life-ending diagnosis.

In summary, a high index of suspicion for orbital recurrence should be maintained in any patient with prior history of melanoma, however distant the primary tumor is in site or time. Furthermore, giving a prognosis for orbital melanoma remains problematic due to highly variable survival, and further investigation will be necessary to understand the likely genetic basis of this phenomenon. Currently, surgery remains the mainstay of therapy in melanoma, but development of new immunotherapeutic agents might revolutionize therapy in the years to come.
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